OSE is advancing an "Immunotherapy 2.0" future by leveraging MAbSilico’s artificial intelligence-powered software solutions and professional services to accelerate and further optimize the development ...
NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) (Paris:OSE), today announced that the Japanese Patent Office has issued the notice of ...
Nantes, France – February 22, 2023, 6:00 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the online publication in the peer-reviewed ‘The Journal of Immunology’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback